{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:43:02Z","timestamp":1783618982505,"version":"3.55.0"},"reference-count":16,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T00:00:00Z","timestamp":1646784000000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To evaluate sex differences in demographic and clinical characteristics, treatments and outcomes for patients with diagnosed obstructive hypertrophic cardiomyopathy (oHCM) in the USA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Retrospective observational study of administrative claims data from MarketScan Commercial Claims and Encounters Database from IBM Watson Health.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Of the 28 million covered employees and family members in MarketScan, 9306 patients with oHCM were included in this analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measures<\/jats:title><jats:p>oHCM-related outcomes included heart failure, atrial fibrillation, ventricular tachycardia\/ fibrillation, sudden cardiac death, septal myectomy, alcohol septal ablation (ASA) and heart transplant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 9306 patients with oHCM, the majority were male (60.5%, p&lt;0.001) and women were of comparable age to men (50\u00b115 vs 49\u00b115 years, p&lt;0.001). Women were less likely to be prescribed beta blockers (42.7% vs 45.2%, p=0.017) and undergo an implantable cardioverter-defibrillator (1.7% vs 2.6%, p=0.005). Septal reduction therapy was performed slightly more frequently in women (ASA: 0.08% vs 0.05%, p=0.600; SM: 0.35% vs 0.18%, p=0.096), although not statistically significant. Women were less likely to have atrial fibrillation (6.7% vs 9.9%, p&lt;0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Women were less likely to be prescribed beta blockers, ACE inhibitors, anticoagulants, undergo implantable cardioverter-defibrillator and have ventricular tachycardia\/fibrillation. Men were more likely to have atrial fibrillation. Future research using large, clinical real-world data are warranted to understand the root cause of these potential treatment disparities in women with oHCM.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2021-058151","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T16:21:01Z","timestamp":1646842861000},"page":"e058151","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Sex differences in clinical outcomes for obstructive hypertrophic cardiomyopathy in the USA: a retrospective observational study of administrative claims data"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6015-7910","authenticated-orcid":false,"given":"Michael","family":"Butzner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yendelela","family":"Cuffee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S","family":"Hollenbeak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sciamanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore P","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"2023030803132613000_12.3.e058151.1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.117.311059"},{"key":"2023030803132613000_12.3.e058151.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.950089"},{"key":"2023030803132613000_12.3.e058151.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021332"},{"key":"2023030803132613000_12.3.e058151.4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006657"},{"key":"2023030803132613000_12.3.e058151.5","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012041","article-title":"Impact of sex on clinical course and survival in the contemporary treatment era for hypertrophic cardiomyopathy","volume":"8","author":"Rowin","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2023030803132613000_12.3.e058151.6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx527"},{"key":"2023030803132613000_12.3.e058151.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.04.043"},{"key":"2023030803132613000_12.3.e058151.8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0102969"},{"key":"2023030803132613000_12.3.e058151.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2008.01.005"},{"key":"2023030803132613000_12.3.e058151.10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.117.004133"},{"key":"2023030803132613000_12.3.e058151.11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jamacardio.2019.0084","article-title":"Survival differences in women and men after septal myectomy for obstructive hypertrophic cardiomyopathy","volume":"4","author":"Meghji","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2023030803132613000_12.3.e058151.12","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.amjcard.2018.08.040","article-title":"Effect of gender and genetic mutations on outcomes in patients with hypertrophic cardiomyopathy","volume":"122","author":"van Velzen","year":"2018","journal-title":"Am J Cardiol"},{"key":"2023030803132613000_12.3.e058151.13","doi-asserted-by":"crossref","first-page":"765876","DOI":"10.3389\/fcvm.2021.765876","article-title":"Stable rates of obstructive hypertrophic cardiomyopathy in a contemporary era","volume":"8","author":"Butzner","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2023030803132613000_12.3.e058151.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.08.021"},{"key":"2023030803132613000_12.3.e058151.15","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eur360"},{"key":"2023030803132613000_12.3.e058151.16","first-page":"32022","article-title":"Sex Differences in the Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy [published online ahead of print, 2021 Jan 4]","volume":"S1936-8798","author":"Sreenivasan","year":"2021","journal-title":"JACC Cardiovasc Interv"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2021-058151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T12:08:19Z","timestamp":1678277299000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2021-058151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,28]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/bmjopen-2021-058151"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2021-058151","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}